KRIBB Licenses ERGO™ Genomics Platform to Identify Biological Products in Microbes
News Jul 16, 2007
Korean Research Institute of Bioscience and Biotechnology(KRIBB) has licensed the ERGO&trade bioinformatics software developed and maintained by Integrated Genomics.
KRIBB will utilize the ERGO™ genome analysis tools for gene annotation, metabolic reconstruction and enzyme data-mining as well as for comparative genomics purposes.
"The ERGO platform gives us a valuable and comprehensive resource for our genomics studies and provides a powerful data-mining environment for our systems biology scientists" said Dr Dooil Kim, Professor at the System Microbiology Research Center Division at KRIBB.
Optimized for analysis of microorganisms, ERGO™ integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature. Reaching beyond conventional systems for functional analysis by DNA sequence alone, Integrated Genomics' platform combines pattern-based analyses with a repertoire of comparative genomics tools for gene visualization in the contexts of regulation, expression data, phylogeny, chromosomal neighborhoods and gene fusions.
According to Integrated Genomics, ERGO contains more than 1236 genomes at various stages of completion, as well as the largest available collection of networked cellular pathways.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.